bupivacaine + meloxicam + ketorolac

A combination of **bupivacaine**, **meloxicam**, and **ketorolac** consists of three agents with complementary mechanisms for multimodal pain management following surgery. - **Bupivacaine** is a local anesthetic that blocks sodium channels, preventing nerve impulse transmission and leading to localized numbness and loss of pain sensation. - **Meloxicam** is a nonsteroidal anti-inflammatory drug (NSAID) that inhibits cyclooxygenase (COX) enzymes, decreasing prostaglandin synthesis and thereby mitigating inflammation and pain. - **Ketorolac** is another NSAID with strong analgesic properties, also acting through COX inhibition to reduce prostaglandin production. Used together (typically as a perioperative or postoperative formulation), this combination is intended to provide enhanced, sustained analgesia and reduce opioid requirements. The synergy arises from targeting both peripheral (inflammatory) and central (nervous) components of pain. While combinations of bupivacaine and meloxicam (e.g., Zynrelef) are marketed and studied for postsurgical pain[2][3][4][5][6], clinical trials have investigated bupivacaine combined with ketorolac for extended postoperative pain control[1]. However, a fixed product or standardized formulation combining all three ingredients has not appeared in regulatory databases or commercial offerings and may represent an investigational or off-label practice rather than a commercial product.